Mass spectometry-based protein patterns in the diagnosis of sepsis/systemic inflammatory response syndrome

Shock

Volumn 36, Issue 6, 2011, Pages 560-569

  Kiehntopf, Michael ^a   Schmerler, Diana ^a   Brunkhorst, Frank Martin ^a   Winkler, Robert ^b   Ludewig, Katrin ^a   Osterloh, Dirk ^c   Bloos, Frank ^a   Reinhart, Konrad ^a   Deufel, Thomas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c SIRS Lab GmbH   (Germany)

Author keywords

Clinical proteomics; mass spectrometry; pattern recognition; plasma profiling; protease inhibitors; sepsis; systemic inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; APROTININ; PREALBUMIN;

ADULT; AGED; ARTICLE; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DECISION TREE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SEPSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURGICAL PATIENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 81755165910     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318237ea7c     Document Type: Article

References (38)

1. Rangel-Frausto MS: The epidemiology of bacterial sepsis. Infect Dis Clin North Am 13:299-312, vii, 1999.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001. (Pubitemid 32641789)
3. Chalfin DB, Teres D, Rapoport J: A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC). Crit Care Med 31:306-308, 2003. (Pubitemid 36151190)
4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003. (Pubitemid 36444440)
5. Marshall JC: Sepsis: current status, future prospects. Curr Opin Crit Care 10:250-264, 2004. (Pubitemid 38982140)
6. Marshall JC, Reinhart K: Biomarkers of sepsis. Crit Care Med 37:2290-2298, 2009.
7. Mitaka C: Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 351:17-29, 2005. (Pubitemid 39567312)
8. Ruokonen E, Ilkka L, Niskanen M, Takala J: Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 46:398-404, 2002. (Pubitemid 34454435)
9. Suprin E, Camus C, Gacouin A, Le Tulzo Y, Lavoue S, Feuillu A, Thomas R: Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med 26:1232-1238, 2000.
10. Giamarellos-Bourboulis EJ, Giannopoulou P, Grecka P, Voros D, Mandragos K, Giamarellou H: Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis? J Crit Care 19:152-157, 2004. (Pubitemid 39299181)
11. Marshall JC: Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2:391-405, 2003. (Pubitemid 37361709)
12. Kiehntopf M, Siegmund R, Deufel T: Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 45:1435-1449, 2007. (Pubitemid 350036581)
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
14. Vlahou A, Schorge JO, Gregory BW, Coleman RL: Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol 2003:308-314, 2003.
15. Glaser CB, Chamorro M, Crowley R, Karic L, Childs A, Calderon M: The isolation of alpha-1-protease inhibitor by a unique procedure designed for industrial application. Analytical biochemistry 124:364-371, 1982. (Pubitemid 13204525)
16. Vissers MC, George PM, Bathurst IC, Brennan SO, Winterbourn CC: Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils. J Clin Invest 82:706-711, 1988.
17. Diamandis EP: Serum proteomic profiling by matrix-assisted laser desorptionionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 66:5540-5541, 2006. (Pubitemid 43927101)
18. Myron Johnson A, Merlini G, Sheldon J, Ichihara K: Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 45:419-426, 2007.
19. Escher N, Kaatz M, Melle C, Hipler C, Ziemer M, Driesch D, Wollina U, von Eggeling F: Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia 9:254-259, 2007. (Pubitemid 46457242)
20. Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA: Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 28:713-718, 2007. (Pubitemid 46349354)
21. Ando Y: Transthyretin: it's miracle function and pathogenesis [Japanese]. Rinsho Byori 57:228-235, 2009.
22. Liz MA, Faro CJ, Saraiva MJ, Sousa MM: Transthyretin, a new cryptic protease. J Biol Chem 279:21431-21438, 2004. (Pubitemid 38656553)
23. Liz MA, Gomes CM, Saraiva MJ, Sousa MM: ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 48:2385-2395, 2007. (Pubitemid 350058750)
24. McGillicuddy FC, de la Lleera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP: Inflammation impairs reverse cholesterol transport in vivo. Circulation 119:1135-1145, 2009.
25. Ferard G, Gaudias J, Bourguignat A, Ingenbleek Y: C-reactive protein to transthyretin ratio for the early diagnosis and follow-up of postoperative infection. Clin Chem Lab Med 40:1334-1338, 2002. (Pubitemid 36032678)
26. Gonzales DA, De Torre C, Wang H, et al.: Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia. Proteomics 10:4270-4280, 2010.
27. Pott GB, Chan ED, Dinarello CA, Shapiro L: alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 85:886-895, 2009.
28. Nita IM, Serapinas D, Janciauskiene SM: alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol 39:1165-1176, 2007. (Pubitemid 46819133)
29. Janciauskiene SM, Nita IM, Stevens T: alpha1-Antitrypsin, old dog, new tricks. alpha1-Antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 282:8573-8582, 2007. (Pubitemid 47093518)
30. Janciauskiene S: Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 1535:221-235, 2001. (Pubitemid 32241132)
31. Subramaniyam D, Glader P, von Wachenfeldt K, Burneckiene J, Stevens T, Janciauskiene S: C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol 38:563-575, 2006. (Pubitemid 43117580)
32. Suda K, Takeuchi H, Hagiwara T, et al.: Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock 33:526-531, 2010.
33. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z: The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102:647-655, 2000.
34. Vanlaere I, Libert C: Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 22:224-239, table of contents, 2009.
35. Buhimschi IA, Zhao G, Rosenberg VA, Abdel-Razeq S, Thung S, Buhimschi CS: Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS ONE 3:e2049, 2008.
36. Liotta LA, Petricoin EF: Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30, 2006. (Pubitemid 43121786)
37. Hashiguchi T, Tanaka K, Lee LJ, Sasaki K, Natsugoe S, Kawahara K, Arimura K, Maruyama I: Diagnostic value of serum peptidome analyses for protease activated pathological conditions beyond cancer diagnosis. Med Hypotheses 73:760-763, 2009.
38. Banks RE: Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin Chem 54:6-7, 2008. (Pubitemid 351182588)